<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074706</url>
  </required_header>
  <id_info>
    <org_study_id>Hema-C19-Vax</org_study_id>
    <nct_id>NCT05074706</nct_id>
  </id_info>
  <brief_title>Evaluation of the Immune Response to Sars-Cov-2 Vaccines in Haematological Patients: Prospective Single Center Study</brief_title>
  <acronym>Hema-C19-Vax</acronym>
  <official_title>Evaluation of the Immune Response to Sars-Cov-2 Vaccines in Haematological Patients: Prospective Single Center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>San Gerardo Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Milano Bicocca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to investigate the humoral immune response to COVID-19&#xD;
      vaccines in haematological patients, by testing SARS-CoV-2 seroconversion&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single-center prospective study will enroll approximately 700 hematologic patients who&#xD;
      access to Haematological Division (San Gerardo Hospital, Monza, Italy) in order to perform&#xD;
      their routine blood tests to monitor their hematological conditions. Evaluation of Sars-Cov-2&#xD;
      IgG specific antibodies will be performed on left-over biological material (serum or plasma)&#xD;
      collected during routine blood tests run between 30 and 60 days after the administration of&#xD;
      the second vaccine dose.&#xD;
&#xD;
      Furthermore, in each patient who has failed seroconversion (absence of specific antibodies&#xD;
      for circulation), his cellular immune response will be assessed using an additional blood&#xD;
      sample collected during routine blood tests.&#xD;
&#xD;
      These samples will be collected within 9 months of the completion of the vaccination series&#xD;
      and will be used to evaluate the plasma INF-γ release using QuantiFERON SARS-CoV-2 test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of seroconversion in hematological patients who received a mRNA SARS-CoV-2 vaccine</measure>
    <time_frame>Between 30 and 60 days after the administration of the second vaccine dose</time_frame>
    <description>Seroconversion is defined as a post-vaccination SARS-CoV-2 IgG antibody titer &gt;33.8 Binding Anticorpal Unit (BAU)/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the seroconversion rate in haematological patients versus healthy subjects.</measure>
    <time_frame>Between 30 and 60 days after the administration of the second vaccine dose</time_frame>
    <description>Time adjusted rate of seroconversion after vaccination in hematological patient and healthy population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate the rate of seroconversion in hematological patients to the specific haematological diseases.</measure>
    <time_frame>Between 30 and 60 days after the administration of the second vaccine dose</time_frame>
    <description>Rate of seroconversion per type of haematological condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate the rate of seroconversion to previous therapies</measure>
    <time_frame>Between 30 and 60 days after the administration of the second vaccine dose</time_frame>
    <description>Rate of seroconversion per specific treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of vaccine by estimating how many patients will be infected by SARS-CoV-2 in the 9 months after the administration of the second vaccine dose.</measure>
    <time_frame>Within 9 months after the administration of the second vaccine dose</time_frame>
    <description>Rate of patients with a positive RT-PCR-SARS-CoV-2 test in the 9 months after the administration of the second vaccine dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analize T-cell response in those patients who will result negative for specific antibodies anti-Sars-Cov-2 after two doses of mRNA SARS-Cov-2 vaccination</measure>
    <time_frame>Within 9 months after the administration of the second vaccine dose</time_frame>
    <description>Rate of patients with a positive QuantiFERON-SARS-CoV-2 test after the demonstration of seroconversion failure until the end of the study</description>
  </secondary_outcome>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Hematologic Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IgG antibodies to Sars-Cov-2</intervention_name>
    <description>Samples will be collected between 30 and 60 days after second vaccine dose.</description>
    <other_name>Blood serum SARS-CoV-2 IgG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QuantiFERON SARS-CoV-2 test</intervention_name>
    <description>Samples will be collected within 9 months after completion of the vaccination series</description>
    <other_name>Plasma INF-γ</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Haematological patients followed at the Haematological Division, San Gerardo Hospital,&#xD;
        Monza, Italy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated EC-approved informed consent&#xD;
&#xD;
          -  Hematological disease defined according to World Health Organization (WHO) criteria&#xD;
&#xD;
          -  Female or male, 18 years of age or older&#xD;
&#xD;
          -  ECOG performance status 0-3&#xD;
&#xD;
          -  Willingness and ability to comply with routine clinical practice and study procedures&#xD;
&#xD;
          -  Regular vaccination against SARS-CoV-2 according to Italian Haematological Society&#xD;
             (SIE) guidelines/recommendations (Version 2.0, 20 April, 2021).&#xD;
&#xD;
          -  Routine blood test planned between 30 and 60 days after administration of the second&#xD;
             vaccine dose according to regular hematological follow up.&#xD;
&#xD;
          -  Routine blood test planned no later than 9 months after the completion of the&#xD;
             vaccination series (only in case of absence of circulation specific antibodies).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preventive vaccination against SARS-CoV-2 not administered according to Italian&#xD;
             Haematological Society (SIE) guidelines/recommendations (Version 2.0, 20 April, 2021)&#xD;
&#xD;
          -  Evidence of previous infection with the SARS-Cov-2 virus.&#xD;
&#xD;
          -  Routine blood test not planned between 30 and 60 days after administration of the&#xD;
             second vaccine dose.&#xD;
&#xD;
          -  Routine blood test not planned within 9 months after the completion of the vaccination&#xD;
             series (only in case of absence of circulation specific antibodies).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Gambacorti Passerini, Professor</last_name>
    <role>Study Director</role>
    <affiliation>San Gerardo Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisa Bossi, MD</last_name>
    <phone>+39 0392339394</phone>
    <email>carlo.gambacorti@unimib.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Aroldi, M.Sc</last_name>
    <phone>+39 039 2333435</phone>
    <email>andrea.aroldi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>San Gerardo Hospital</name>
      <address>
        <city>Monza</city>
        <state>Lombardia</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Gambacorti Passerini, Professor</last_name>
      <phone>+39 0392339553</phone>
      <email>carlo.gambacorti@unimib.it</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Ciulla, M.Sc</last_name>
      <phone>+39 0392333435</phone>
      <email>d.ciulla.hsg@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>serocoversion</keyword>
  <keyword>COVID vaccination</keyword>
  <keyword>cellular immunity</keyword>
  <keyword>Sars-Cov-2 IgG antibodies</keyword>
  <keyword>QuantiFERON-SARS-CoV-2 test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

